Comparison of the efficacy and safety of bupropion versus aripiprazole augmentation in adults with treatment-resistant depression: a nationwide cohort study in South Korea by Dong Yun Lee, Rae Woong Park, Soo Min Jeon

Subjects: Get full text

Trajectory of peripheral inflammation during index ECT in association with clinical outcomes in treatment-resistant depression by Christina M. Hough, Jennifer L. Kruse, Randall T. Espinoza, John O. Brooks, III, Eliza J. Congdon, Viviane Norris, Michelle G. Craske, Katherine L. Narr

“…Improved understanding of these processes may provide critical insight into effective intervention for treatment-resistant depression (TRD). Methods: Plasma inflammatory markers were assessed at pre-treatment (T1), after the second ECT session (T2), and after ECT index series completion (post-treatment/T3) in TRD (n = 40). …”
Get full text

Predicting treatment response to ketamine in treatment-resistant depression using auditory mismatch negativity: Study protocol. by Josh Martin, Fatemeh Gholamali Nezhad, Alice Rueda, Gyu Hee Lee, Colleen E Charlton, Milad Soltanzadeh, Karim S Ladha, Sridhar Krishnan, Andreea O Diaconescu, Venkat Bhat

“…<h4>Background</h4>Ketamine has recently attracted considerable attention for its rapid effects on patients with major depressive disorder, including treatment-resistant depression (TRD). Despite ketamine's promising results in treating depression, a significant number of patients do not respond to the treatment, and predicting who will benefit remains a challenge. …”
Get full text

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial by Hiroaki Hori, Hiroshi Kunugi

“…Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression. Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD). …”
Get full text

Trazodone Addition to Paroxetine and Mirtazapine in a Patient with Treatment-Resistant Depression: The Pros and Cons of Combining Three Antidepressants by Rui Lopes, José Carlos Alves, Raquel Garcia Rego

“…Dual antidepressant combination for treatment-resistant depression is a strategy well supported by literature and accepted in clinical practice. …”
Get full text

Therapeutic Approaches to Tackle the Challenge of Depression That Is Resistant to Treatment–A Narrative Review by Md. Rajdoula Rafe, Abdul Waris, Pranoy Saha

Subjects: Get full text

Personalised transcranial magnetic stimulation for treatment-resistant depression, depression with comorbid anxiety and negative symptoms of schizophrenia: a narrative review by Xiao Wei Tan, Hasvinjit Kaur Gulwant Singh, Jovi Zheng Jie Koh, Rachel Si Yun Tan, Phern Chern Tor

Get full text

A meta-analysis comparing the effectiveness and safety of repetitive transcranial magnetic stimulation versus theta burst stimulation for treatment-resistant depression by Xiao Tao, Zheng Wen Jing, Wang Kui Yuan, Guo Hui Yun, Xie Jian Fang, Liao Ming Sheng

Subjects: Get full text

Respiratory disease in people with Major Depressive Disorder: A Systematic Review and Meta-analysis by Ana Jiménez-Peinado, David Laguna-Muñoz, María José Jaén-Moreno, Cristina Camacho-Rodríguez, Gloria Isabel del Pozo, Eduard Vieta, Javier Caballero-Villarraso, Fernando Rico-Villademoros, Fernando Sarramea

Subjects: Get full text

Ketamine Therapy in Complex Cases: A Cautionary Tale of Exacerbated Personality Traits and the Crucial Role of Comprehensive Follow-Up and Psychosocial Interventions by Jai Ahuja, Luba Leontieva

“…This case report examines the unexpected increase in suicidal ideation following ketamine infusion therapy in a 75-year-old female with a history of treatment-resistant depression. Despite ketamine’s established efficacy in treating depression and acute suicidality, this patient’s condition deteriorated posttreatment. …”
Get full text

A Case of Hepatotoxicity Induced by Therapeutic Ketamine Use for Sedation by Noah Yoo, Sarun Thomas, Michael Bender, Xian Jie Cindy Cheng

“…Ketamine, initially developed as an anesthetic, has shown versatility in medical applications, including pain management, treatment-resistant depression, and sedation in the intensive care unit (ICU). …”
Get full text

Testosterone Replacement Therapy in the Treatment of Depression by Danyon J. Anderson, Parsia Vazirnia, Catherine Loehr, Whitney Sternfels, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits

“… # Results Within some subpopulations such as men with dysthymic disorder, treatment resistant depression, or low testosterone levels, testosterone administration yielded positive results in the treatment of depression. …”
Get full text

Trends in research on novel antidepressant treatments by Agnieszka Zelek-Molik, Ewa Litwa

“…The development of rapid-acting drugs is increasingly focused on achieving high efficacy, particularly for treatment-resistant depression. Such advances offer the potential for rapid therapeutic effects without the prolonged and often tedious administration of older generation antidepressants. …”
Get full text

Is there a risk of esketamine misuse in clinical practice? by Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman, Marta Torrens, Pablo Vega, Pilar Andres-Olivera, Francisco Javier Álvarez

“…In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. …”
Get full text

Role of Ketamine in the Treatment of Psychiatric Disorders by Sahar Derakhshanian, Maxine Zhou, Alexander Rath, Rachel Barlow, Sarah Bertrand, Caroline DeGraw, Christopher Lee, Jamal Hasoon, Alan D. Kaye

“…# Purpose of review This is a comprehensive review of the literature regarding the use of ketamine as a treatment for treatment-resistant depression (TRD). It covers the epidemiology, risk factors, pathophysiology, and current treatment modalities regarding Major Depressive Disorder (MDD) and TRD. …”
Get full text

Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling by Ginetta Collo, Laura Cavalleri, Federica Bono, Cristina Mora, Stefania Fedele, Roberto William Invernizzi, Massimo Gennarelli, Giovanna Piovani, Tilo Kunath, Mark J. Millan, Emilio Merlo Pich, PierFranco Spano

“…The antiparkinsonian ropinirole and pramipexole are D3 receptor- (D3R-) preferring dopaminergic (DA) agonists used as adjunctive therapeutics for the treatment resistant depression (TRD). While the exact antidepressant mechanism of action remains uncertain, a role for D3R in the restoration of impaired neuroplasticity occurring in TRD has been proposed. …”
Get full text

THE PLANNING AND ORGANIZATION OF ECT TREATMENTS IN FINLAND – RESULTS FROM A NATIONAL SURVEY by SAANA KARTTUNEN, LAURI VIRTANEN, ANU HOLM, NIKO SEPPÄLÄ, PETRI SUMIA, ERIKA JÄÄSKELÄINEN, KAIJA JÄRVENTAUSTA

“…In 91% of the units, catatonia patients were able to start ECT within a week, whereas for non-acute outpatients with treatment-resistant depression, the waiting time in 57% of the units was 1-3 months, and in one unit over one year. …”
Get full text

Major Depressive Disorder as a Condition Negatively Impacting Both Mental and Physical Functioning. What to Do When There Is Treatment Resistance? by Monika Makar, Daria Michałka, Zuzanna Gałuszka, Natalie Papachristoforou, Justyna Głowacka, Aleksandra Kocjan, Emilia Bąk, Natalia Tekiela, Radosław Chmiel, Tomasz Bartuś

“… The objective of this article is to assess the efficacy and safety of diverse therapeutic strategies for treatment-resistant depression (TRD), encompassing both pharmacological and non-pharmacological interventions. …”
Get full text

S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study by Domenico De Berardis, Stefano Marini, Nicola Serroni, Gabriella Rapini, Felice Iasevoli, Alessandro Valchera, Maria Signorelli, Eugenio Aguglia, Giampaolo Perna, Anatolia Salone, Giuseppe Di Iorio, Giovanni Martinotti, Massimo Di Giannantonio

“…We investigated the efficacy of S-Adenosyl-L-Methionine (SAMe) augmentation in patients with treatment-resistant depressive disorder (TRD). Thirty-three outpatients with major depressive episode who failed to respond to at least 8 weeks of treatment with two adequate and stable doses of antidepressants were treated openly with fixed dose of SAMe (800 mg) for 8 weeks, added to existing medication. …”
Get full text